Collegium Pharmaceutical, Inc.
COLL
$34.87
-$0.82-2.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.81% | -1.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.81% | -1.87% | |||
| Cost of Revenue | -3.69% | -0.28% | |||
| Gross Profit | -6.05% | -2.05% | |||
| SG&A Expenses | 29.53% | 1.70% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.14% | 0.74% | |||
| Operating Income | -49.94% | -7.45% | |||
| Income Before Tax | -35.46% | -33.15% | |||
| Income Tax Expenses | -64.85% | 1.21% | |||
| Earnings from Continuing Operations | -14.54% | -46.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.54% | -46.16% | |||
| EBIT | -49.94% | -7.45% | |||
| EBITDA | -26.48% | -4.12% | |||
| EPS Basic | -15.69% | -46.30% | |||
| Normalized Basic EPS | -59.80% | -4.50% | |||
| EPS Diluted | -91.87% | -45.10% | |||
| Normalized Diluted EPS | -59.24% | -5.78% | |||
| Average Basic Shares Outstanding | 1.37% | 0.26% | |||
| Average Diluted Shares Outstanding | -0.03% | 1.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||